1887

Abstract

Measles virus (MV)-neutralizing antibodies in sera from vaccinated subjects are mainly directed against the haemagglutinin (H) protein. It has been shown previously that depletion of vaccination-induced H-specific antibodies by co-culture of sera with cells expressing the MV Edmonston strain H glycoprotein resulted in almost complete elimination of neutralizing activity. In the present study, MV H and/or fusion (F) protein-specific antibodies were depleted from sera of naturally immune subjects. Early convalescent samples were collected 1.5 years after a well-characterized measles outbreak in Luxembourg caused by a genotype C2 virus, whilst late convalescent samples were collected from healthy Dutch subjects born between 1960 and 1970. Depletion of both H- and F-specific antibodies completely eliminated virus-neutralizing (VN) activity against MV Edmonston. However, in the early convalescent samples, residual VN antibody against wild-type MV genotype C2 was detected. This demonstrated that, although the majority of MV-specific VN antibodies recognized epitopes conserved between different genotypes, genotype-specific VN epitopes were also induced. In sera depleted of H-specific antibodies only, VN activity against MV Edmonston was not completely eliminated, demonstrating the presence of F-specific VN antibodies. In conclusion, this study demonstrated that a fraction of VN antibodies induced by wild-type MV genotype C2 does not neutralize MV strain Edmonston. In addition, it was shown that, in sera from naturally immune donors, the majority of VN antibodies are specific for MV H protein, but up to 10 % of neutralizing antibodies are specific for MV F protein.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.014944-0
2009-12-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/90/12/2982.html?itemId=/content/journal/jgv/10.1099/vir.0.014944-0&mimeType=html&fmt=ahah

References

  1. Armstrong, M. A., Fraser, K. B. & Shirodaria, P. V. ( 1979; ). The sensitivity of measles virus haemolysin to acetone and the preparation of monospecific human anti-haemolysin by absorption. J Gen Virol 44, 541–544.[CrossRef]
    [Google Scholar]
  2. Atabani, S. F., Obeid, O. E., Chargelegue, D., Aaby, P., Whittle, H. & Steward, M. W. ( 1997; ). Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection. J Virol 71, 7240–7245.
    [Google Scholar]
  3. Bouche, F. B., Ertl, O. T. & Muller, C. P. ( 2002; ). Neutralizing B cell response in measles. Viral Immunol 15, 451–471.[CrossRef]
    [Google Scholar]
  4. Chen, R. T., Markowitz, L. E., Albrecht, P., Stewart, J. A., Mofenson, L. M., Preblud, S. R. & Orenstein, W. A. ( 1990; ). Measles antibody: reevaluation of protective titers. J Infect Dis 162, 1036–1042.[CrossRef]
    [Google Scholar]
  5. De Serres, G., Boulianne, N., Meyer, F. & Ward, B. J. ( 1995; ). Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiol Infect 115, 315–323.[CrossRef]
    [Google Scholar]
  6. de Swart, R. L., Vos, H. W., UytdeHaag, F. G. C. M., Osterhaus, A. D. M. E. & van Binnendijk, R. S. ( 1998; ). Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay. J Virol Methods 71, 35–44.[CrossRef]
    [Google Scholar]
  7. de Swart, R. L., Yüksel, S. & Osterhaus, A. D. M. E. ( 2005; ). Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol 79, 11547–11551.[CrossRef]
    [Google Scholar]
  8. de Swart, R. L., Ludlow, M., De Witte, L., Yanagi, Y., Van Amerongen, G., McQuaid, S., Yüksel, S., Geijtenbeek, T. B. H., Duprex, W. P. & Osterhaus, A. D. M. E. ( 2007; ). Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 3, e178 [CrossRef]
    [Google Scholar]
  9. El Mubarak, H. S., Van de Bildt, M. W. G., Mustafa, O. A., Vos, H. W., Mukhtar, M. M., Groen, J., El Hassan, A. M., Niesters, H. G. M., Ibrahim, S. A. & other authors ( 2000; ). Serological and virological characterization of clinically diagnosed cases of measles in suburban Khartoum. J Clin Microbiol 38, 987–991.
    [Google Scholar]
  10. Enders, J. F. & Peebles, T. C. ( 1954; ). Propagation in tissue cultures of cytopathic agents from patients with measles. Proc Soc Exp Biol Med 86, 277–286.[CrossRef]
    [Google Scholar]
  11. Fayolle, J., Verrier, B., Buckland, R. & Wild, T. F. ( 1999; ). Characterization of a natural mutation in an antigenic site on the fusion protein of measles virus that is involved in neutralization. J Virol 73, 787–790.
    [Google Scholar]
  12. Fine, P. E. & Zell, E. R. ( 1994; ). Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am J Epidemiol 139, 77–90.
    [Google Scholar]
  13. Frank, S. A. & Bush, R. M. ( 2007; ). Barriers to antigenic escape by pathogens: trade-off between reproductive rate and antigenic mutability. BMC Evol Biol 7, 229 [CrossRef]
    [Google Scholar]
  14. Griffin, D. E. ( 2007; ). Measles virus. In Fields Virology, 5th edn, pp. 1551–1585. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.
  15. Hanses, F., Van Binnendijk, R. S., Ammerlaan, W., Truong, A. T., De Rond, L., Schneider, F. & Muller, C. P. ( 2000; ). Genetic variability of measles viruses circulating in the Benelux. Arch Virol 145, 541–551.[CrossRef]
    [Google Scholar]
  16. Itoh, M., Okuno, Y. & Hotta, H. ( 2002; ). Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups. J Clin Microbiol 40, 1733–1738.[CrossRef]
    [Google Scholar]
  17. Johnson, J. P., Demmer-Dieckmann, M., Meo, T., Hadam, M. R. & Riethmuller, G. ( 1981; ). Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse origin. Eur J Immunol 11, 825–831.[CrossRef]
    [Google Scholar]
  18. Kühne, M., Brown, D. W. G. & Jin, L. ( 2006; ). Genetic variability of measles virus in acute and persistent infections. Infect Genet Evol 6, 269–276.[CrossRef]
    [Google Scholar]
  19. Muller, C. P., Huiss, S. & Schneider, F. ( 1996; ). Secondary immune responses in parents of children with recent measles. Lancet 348, 1379–1380.
    [Google Scholar]
  20. Ono, N., Tatsuo, H., Hidaka, Y., Aoki, T., Minagawa, H. & Yanagi, Y. ( 2001; ). Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol 75, 4399–4401.[CrossRef]
    [Google Scholar]
  21. Paunio, M., Hedman, K., Davidkin, I., Valle, M., Heinonen, O. P., Leinikki, P., Salmi, A. & Peltola, H. ( 2000; ). Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect 124, 263–271.[CrossRef]
    [Google Scholar]
  22. Reyes, M. A., de Borrero, M. F., Roa, J., Bergonzoli, G. & Saravia, N. G. ( 1987; ). Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J 6, 848–851.[CrossRef]
    [Google Scholar]
  23. Rota, P. A., Featherstone, D. A. & Bellini, W. J. ( 2009; ). Molecular epidemiology of measles virus. Curr Top Microbiol Immunol 330, 129–150.
    [Google Scholar]
  24. Samb, B., Aaby, P., Whittle, H. C., Seck, A. M. C., Rahman, S., Bennett, J., Markowitz, L. & Simondon, F. ( 1995; ). Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 14, 203–209.[CrossRef]
    [Google Scholar]
  25. Santibanez, S., Niewiesk, S., Heider, A., Schneider-Schaulies, J., Berbers, G. A. M., Zimmermann, A., Halenius, A., Wolbert, A., Deitemeier, I. & other authors ( 2005; ). Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? J Gen Virol 86, 365–374.[CrossRef]
    [Google Scholar]
  26. Sastre, P., Melero, J. A., García-Barreno, B. & Palomo, C. ( 2005; ). Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. J Med Virol 76, 248–255.[CrossRef]
    [Google Scholar]
  27. Sato, T. A., Kohama, T. & Sugiura, A. ( 1989; ). Protective role of human antibody to the fusion protein of measles virus. Microbiol Immunol 33, 601–607.[CrossRef]
    [Google Scholar]
  28. Sutcliffe, P. A. & Rea, E. ( 1996; ). Outbreak of measles in a highly vaccinated secondary school population. CMAJ 155, 1407–1413.
    [Google Scholar]
  29. Tamin, A., Rota, P. A., Wang, Z.D., Heath, J. L., Anderson, L. J. & Bellini, W. J. ( 1994; ). Antigenic analysis of current wild type and vaccine strains of measles virus. J Infect Dis 170, 795–801.[CrossRef]
    [Google Scholar]
  30. van Binnendijk, R. S., Poelen, M. C. M., de Vries, P., Voorma, H. O., Osterhaus, A. D. M. E. & UytdeHaag, F. G. C. M. ( 1989; ). Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones. J Immunol 142, 2847–2854.
    [Google Scholar]
  31. van den Hof, S., Berbers, G. A. M., de Melker, H. E. & Conyn-van Spaendonck, M. A. E. ( 1999; ). Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccination coverage. Vaccine 18, 931–940.[CrossRef]
    [Google Scholar]
  32. WHO ( 2008; ). Progress in global measles control and mortality reduction, 2000–2007. Wkly Epidemiol Rec 83, 441–448.
    [Google Scholar]
  33. Wiesmüller, K.-H., Spahn, G., Handtmann, D., Schneider, F., Jung, G. & Muller, C. P. ( 1992; ). Heterogeneity of linear B cell epitopes of the measles virus fusion protein reacting with late convalescent sera. J Gen Virol 73, 2211–2216.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.014944-0
Loading
/content/journal/jgv/10.1099/vir.0.014944-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error